Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

By B. Pro, R. Advani, P. Brice, N. Bartlett, J. Rosenblatt, T. Illidge, J. Matous, R. Ramchandren, M. Fanale, J. Connors and 4 more. Journal of Clinical Oncology, 2012

969 citations recorded by the source corpus.

Subfields: Dermatology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/db156a3ba0a065ff7e69d799de99b28cfcc93ba0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Shi
2. Shijun Li
3. Zhiwen Fu
4. Yu Zhang
5. Sifei Han

Citations in the corpus

• Antibody drug conjugate: the “biological missile” for targeted cancer therapy (2022, result): “The severe AEs observed in patients with sALCL were similar with those with SCT.162 In November 2017, brentuximab vedotin received additional approval as a treatment for primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior system”